News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
267,570 Results
Type
Article (14537)
Company Profile (281)
Press Release (252752)
Section
Business (81130)
Career Advice (164)
Deals (13460)
Drug Delivery (32)
Drug Development (51845)
Employer Resources (35)
FDA (6209)
Job Trends (5489)
News (148415)
Policy (10531)
Tag
Academia (951)
Alliances (21845)
Alzheimer's disease (724)
Approvals (6174)
Artificial intelligence (50)
Bankruptcy (97)
Best Places to Work (4791)
Biotechnology (230)
Breast cancer (46)
Cancer (469)
Career advice (143)
CAR-T (38)
Cell therapy (128)
Clinical research (40807)
Collaboration (162)
Compensation (72)
COVID-19 (1042)
Cystic fibrosis (61)
Data (450)
Diabetes (53)
Diagnostics (1276)
Earnings (29510)
Events (47109)
Executive appointments (139)
FDA (6407)
Featured Employer (37)
Funding (161)
Gene editing (37)
Gene therapy (105)
GLP-1 (278)
Government (1126)
Healthcare (6872)
Infectious disease (1064)
Inflammatory bowel disease (86)
IPO (7323)
Job creations (871)
Job search strategy (134)
Layoffs (183)
Legal (1420)
Lung cancer (90)
Manufacturing (52)
Medical device (2944)
Medtech (2945)
Mergers & acquisitions (6189)
Metabolic disorders (175)
Neuroscience (885)
NextGen Class of 2024 (2054)
Non-profit (883)
Northern California (681)
Obesity (100)
Opinion (91)
Parkinson's disease (54)
Patents (39)
People (25062)
Pharmaceutical (46)
Phase I (14014)
Phase II (18809)
Phase III (12334)
Pipeline (112)
Postmarket research (978)
Preclinical (5866)
Radiopharmaceuticals (202)
Rare diseases (127)
Real estate (1437)
Regulatory (8540)
Research institute (972)
Southern California (641)
Startups (1991)
United States (5876)
Vaccines (159)
Weight loss (66)
Date
Today (103)
Last 7 days (366)
Last 30 days (1627)
Last 365 days (21610)
2024 (16964)
2023 (23026)
2022 (27669)
2021 (28683)
2020 (24163)
2019 (17003)
2018 (12401)
2017 (14359)
2016 (12424)
2015 (14906)
2014 (10792)
2013 (7795)
2012 (7842)
2011 (7990)
2010 (7759)
Location
Africa (154)
Arizona (41)
Asia (17250)
Australia (2892)
California (1563)
Canada (588)
China (117)
Colorado (54)
Connecticut (59)
Europe (37050)
Florida (168)
Georgia (40)
Illinois (97)
Indiana (57)
Kansas (55)
Maryland (239)
Massachusetts (1273)
Michigan (44)
Minnesota (81)
New Jersey (420)
New York (482)
North Carolina (360)
Northern California (681)
Ohio (67)
Pennsylvania (343)
South America (217)
Southern California (641)
Texas (156)
Washington State (178)
267,570 Results for "frequency therapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Lone Star Bio
Nexalin Technology Awarded Key Patent Related to its Non-Invasive, Frequency-Based Deep-Brain Stimulation Device for the Treatment of Alzheimer’s and Dementia
Nexalin Technology, Inc. announced that the United States Patent and Trademark Office has awarded U.S. Patent No 12,011,591 relating to the Company’s non-invasive Deep Intracranial Frequency Stimulation medical device for the treatment of Alzheimer’s and other dementia-related brain diseases.
June 20, 2024
·
4 min read
Lone Star Bio
Nexalin Technology Awarded Key Patent Related to its Non-Invasive, Frequency-Based Deep-Brain Stimulation Device – the Transcranial Alternating Current Dynamic Frequency Stimulation (TACS) System
Nexalin Technology, Inc. (the “Company” or “Nexalin”) (Nasdaq: NXL; NXLIW) today announced that the United States Patent and Trademark Office (USPTO) has awarded U.S. Patent No. 11,872,397 relating to the Company’s non-invasive, frequency-based deep brain stimulation device.
January 23, 2024
·
4 min read
Lone Star Bio
Nexalin Technology Awarded Key Patent Related to its Gen-3 HALO Clarity™, a Non-Invasive, Frequency-Based Deep-Brain Stimulation Device
Nexalin Technology, Inc. (the “Company” or “Nexalin”) (Nasdaq: NXL; NXLIW) today announced that the United States Patent and Trademark Office (USPTO) has awarded U.S. Patent No. 17/337,653 relating to the Company’s non-invasive, frequency-based deep brain stimulation device.
April 4, 2024
·
3 min read
Elinzanetant significantly reduces frequency and severity of moderate to severe hot flashes associated with menopause
Bayer will present detailed results from the pivotal Phase III studies OASIS 1 and 2, showing that the investigational compound elinzanetant significantly reduced frequency and severity of moderate to severe vasomotor symptoms associated with menopause compared to placebo.
May 16, 2024
·
11 min read
Deals
Korro Bio and Frequency Therapeutics Announce Closing of Merger and Private Placement of $117 Million
Korro Bio, Inc. announced the completion of the previously announced business combination between Frequency Therapeutics, Inc. and the entity formerly known as Korro Bio, Inc.
November 3, 2023
·
9 min read
Deals
UPDATE: Korro Bio and Frequency Therapeutics Announce Closing of Merger and Private Placement of $117 Million
Korro Bio, Inc. announced the completion of the previously announced business combination between Frequency Therapeutics, Inc. and the entity formerly known as Korro Bio, Inc.
November 3, 2023
·
9 min read
Deals
Korro Bio and Frequency Therapeutics Announce Merger Agreement
Korro Bio, Inc. and Frequency Therapeutics, Inc. announced that they have entered into a definitive merger agreement to combine the companies in an all-stock transaction.
July 14, 2023
·
18 min read
Press Releases
New Study Shows Nexalin’s Deep Intracranial Frequency Stimulation (DIFS) Significantly Improves Memory and Cognitive Function in Alzheimer’s Patients
October 18, 2024
·
5 min read
Pharm Country
Olympus Issues Voluntary Field Action to Remind Users of Warnings for Bronchoscopes Used with High-Frequency Therapy Equipment
Olympus Corporation has announced a voluntary field corrective action to address complaints of endobronchial combustion occurring during therapeutic procedures involving use of high-frequency therapy equipment in an oxygenated environment.
November 9, 2023
·
2 min read
Genetown
Frequency Therapeutics to Participate at Upcoming March Investor Conferences
Frequency Therapeutics, Inc. today announced that interim Chief Executive Officer and Chief Scientific Officer Christopher Loose, Ph.D., will present at the following March healthcare investor conferences.
February 27, 2023
·
1 min read
1 of 26,757
Next
